JNJ-42165279
JNJ-42165279 is an experimental drug developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. It is a selective antagonist of the fatty acid amide hydrolase (FAAH) enzyme, which is involved in the breakdown of endocannabinoids in the body. By inhibiting FAAH, JNJ-42165279 increases the levels of endocannabinoids, which are involved in a variety of physiological processes including pain, mood, and inflammation.
Development and Clinical Trials[edit | edit source]
JNJ-42165279 has been investigated in several clinical trials for its potential therapeutic effects. In a Phase 2a study, the drug was found to be safe and well-tolerated in patients with social anxiety disorder and major depressive disorder. However, there were no significant differences in the primary efficacy endpoints between the JNJ-42165279 group and the placebo group.
In another Phase 2a study, JNJ-42165279 was evaluated in patients with neuropathic pain associated with small fiber neuropathy. The results of this study have not yet been published.
Mechanism of Action[edit | edit source]
JNJ-42165279 works by inhibiting the FAAH enzyme, which is responsible for breaking down endocannabinoids in the body. Endocannabinoids are naturally occurring compounds that bind to and activate cannabinoid receptors. These receptors are part of the endocannabinoid system, which plays a key role in regulating a variety of physiological processes, including pain, mood, and inflammation. By inhibiting FAAH, JNJ-42165279 increases the levels of endocannabinoids, potentially enhancing the activity of the endocannabinoid system.
Potential Therapeutic Applications[edit | edit source]
While the clinical trials conducted so far have not demonstrated significant efficacy of JNJ-42165279 in treating social anxiety disorder or major depressive disorder, the drug's mechanism of action suggests that it could potentially be useful in treating a variety of conditions associated with the endocannabinoid system. These could include chronic pain conditions, mood disorders, and inflammatory disorders. However, further research is needed to fully explore these potential applications.
See Also[edit | edit source]
| JNJ-42165279 Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
